Overview

Epidiolex in Typical Absence Seizures

Status:
Enrolling by invitation

Trial end date:
2021-10-05

Target enrollment:

Participant gender:

Summary

This is a Pilot study, open-label study consisting of a screening period of up to 4 weeks, a 4-week dose-titration treatment period to dose of up to 20 mg/kg/day BID of CBD (Epidiolex), and a 30 day safety follow-up period following the last dose of study medication.

Phase:

Phase 4

Details

Lead Sponsor:

University of South Florida

Collaborator:

Greenwich Biosciences

Treatments:

Cannabidiol
Epidiolex